Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Publication Type:

Journal Article


JAMA : the journal of the American Medical Association, Volume 304, Issue 15, p.1684-92 (2010)


2010, Aged, Breast Neoplasms, Center-Authored Paper, Drug Combinations, Estrogens, Conjugated (USP), Female, Follow-Up Studies, Hormone Replacement Therapy, Humans, Incidence, Lymphatic Metastasis, Medroxyprogesterone Acetate, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Postmenopause, Prognosis, Public Health Sciences Division, United States


In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported.